Vaccine trial successes boosted Moderna and Merck, while investors awaited Fed minutes amid geopolitical uncertainty in the Middle East and disappointing OpenAI results.
1 report, 1 independent
Updated Aug 19
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vaccine trial successes boosted Moderna and Merck, while investors awaited Fed minutes amid geopolitical uncertainty in the Middle East and disappointing OpenAI results.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Moderna
American biotechnology company
-
Merck
public company in Indonesia
-
OpenAI
American artificial intelligence research organization
- Leaders call for international cooperation on AI risks, tech leaders call for oversight, and the CMA proposes stricter search engine choice requirements.
- Experts, including Dario Amodei at Cornell University, warned about the power and limits of AI, specifically citing risks of AI taking control of the internet.
-
Federal Open Market Committee
committee of the United States Federal Reserve
Related events
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.
- A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.
- Canadian government, led by PM Mark Carney, meets with OpenAI and debates major tech bills in the House of Commons.
- SoftBank invests in OpenAI amid market declines, while escalating tensions lead to military strikes and Strait of Hormuz closure.